Volume 1, Issue 2 (Multidisciplinary Cancer Investigation 2017)                   Multidiscip Cancer Investig 2017, 1(2): 1-2 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Geijtenbeek T B H. Dendritic Cell Immunotherapy, the Next Step in Cancer Treatment. Multidiscip Cancer Investig 2017; 1 (2) :1-2
URL: http://mcijournal.com/article-1-56-en.html
Abstract:   (5384 Views)

Cancer immunotherapy has gained a lot of interest over the past few years due to the success of immune checkpoint inhibitors in treating cancer (1, 2). Immune checkpoint inhibitors, such as monoclonal antibodies against cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed death 1 (PD-1), have been shown to increase survival of patients with advanced cancers (1, 2). These inhibitors rely on preventing immunosuppression and enhancing anti-tumor responses. Under healthy conditions, over-activation of T cell immunity is controlled by immune checkpoints, which are molecules that suppress T cell function and thereby prevent uncontrolled T cell activation and autoimmunity.

Full-Text [PDF 69 kb]   (3011 Downloads)    
Type of Study: Editorial | Subject: immunotherapy and regenerative medicine
Received: 2016/09/24 | Accepted: 2016/12/3 | ePublished: 2017/04/1

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Multidisciplinary Cancer Investigation

Designed & Developed by : Yektaweb